diff --git a/man/aet01_1.Rd b/man/aet01_1.Rd index 067d13bdd0..7e0332ed52 100644 --- a/man/aet01_1.Rd +++ b/man/aet01_1.Rd @@ -105,21 +105,5 @@ aet01_1 } \examples{ run(aet01_1, syn_test_data(), armvar = "ARM") - -# To create a custom column -library(dm) - -db <- syn_test_data() - -db_add <- db \%>\% - dm_zoom_to(adae) \%>\% - mutate( - RED = .data$AEACN == "DOSE REDUCED", - RED = formatters::with_label(.data$RED, "AE leading to dose reduction") - ) \%>\% - dm_update_zoomed() - -run(aet01_1, db_add, armvar = "ARM", safety_var = c("FATAL", "CTC35", "RED")) - } \keyword{datasets} diff --git a/tests/testthat/_snaps/aet01.md b/tests/testthat/_snaps/aet01.md index 19d5b7999e..d0e7414da7 100644 --- a/tests/testthat/_snaps/aet01.md +++ b/tests/testthat/_snaps/aet01.md @@ -8,19 +8,19 @@ ——————————————————————————————————————————————————————————————————————————————————————————————————————— Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%) Total number of AEs 609 622 703 - Total number of deaths 22 (16.4%) 26 (19.4%) 19 (14.4%) - Total number of patients withdrawn from study due to an AE 6 (4.5%) 1 (0.7%) 2 (1.5%) + Total number of deaths 25 (18.7%) 23 (17.2%) 22 (16.7%) + Total number of patients withdrawn from study due to an AE 3 (2.2%) 6 (4.5%) 5 (3.8%) Total number of patients with at least one AE with fatal outcome 0 (0.0%) 0 (0.0%) 0 (0.0%) Serious AE 0 (0.0%) 0 (0.0%) 0 (0.0%) Serious AE leading to withdrawal from treatment 0 (0.0%) 0 (0.0%) 0 (0.0%) Serious AE leading to dose modification/interruption 0 (0.0%) 0 (0.0%) 0 (0.0%) Related Serious AE 0 (0.0%) 0 (0.0%) 0 (0.0%) - AE leading to withdrawal from treatment 23 (17.2%) 24 (17.9%) 27 (20.5%) - AE leading to dose modification/interruption 72 (53.7%) 65 (48.5%) 76 (57.6%) + AE leading to withdrawal from treatment 27 (20.1%) 26 (19.4%) 30 (22.7%) + AE leading to dose modification/interruption 66 (49.3%) 76 (56.7%) 74 (56.1%) Related AE 105 (78.4%) 108 (80.6%) 109 (82.6%) - Related AE leading to withdrawal from treatment 6 (4.5%) 9 (6.7%) 13 (9.8%) - Related AE leading to dose modification/interruption 31 (23.1%) 31 (23.1%) 32 (24.2%) + Related AE leading to withdrawal from treatment 6 (4.5%) 12 (9.0%) 8 (6.1%) + Related AE leading to dose modification/interruption 29 (21.6%) 38 (28.4%) 38 (28.8%) Severe AE (at greatest intensity) 91 (67.9%) 90 (67.2%) 93 (70.5%) # aet01 can handle some NA values @@ -33,18 +33,18 @@ ——————————————————————————————————————————————————————————————————————————————————————————————————————— Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%) Total number of AEs 609 622 703 - Total number of deaths 22 (16.4%) 26 (19.4%) 19 (14.4%) - Total number of patients withdrawn from study due to an AE 6 (4.5%) 1 (0.7%) 2 (1.5%) + Total number of deaths 25 (18.7%) 23 (17.2%) 22 (16.7%) + Total number of patients withdrawn from study due to an AE 3 (2.2%) 6 (4.5%) 5 (3.8%) Total number of patients with at least one AE with fatal outcome 76 (56.7%) 70 (52.2%) 75 (56.8%) Serious AE 104 (77.6%) 101 (75.4%) 99 (75.0%) - Serious AE leading to withdrawal from treatment 8 (6.0%) 8 (6.0%) 7 (5.3%) - Serious AE leading to dose modification/interruption 36 (26.9%) 31 (23.1%) 26 (19.7%) + Serious AE leading to withdrawal from treatment 9 (6.7%) 6 (4.5%) 11 (8.3%) + Serious AE leading to dose modification/interruption 22 (16.4%) 26 (19.4%) 29 (22.0%) Related Serious AE 76 (56.7%) 70 (52.2%) 75 (56.8%) - AE leading to withdrawal from treatment 23 (17.2%) 24 (17.9%) 27 (20.5%) - AE leading to dose modification/interruption 72 (53.7%) 65 (48.5%) 76 (57.6%) + AE leading to withdrawal from treatment 27 (20.1%) 26 (19.4%) 30 (22.7%) + AE leading to dose modification/interruption 66 (49.3%) 76 (56.7%) 74 (56.1%) Related AE 105 (78.4%) 108 (80.6%) 109 (82.6%) - Related AE leading to withdrawal from treatment 6 (4.5%) 9 (6.7%) 13 (9.8%) - Related AE leading to dose modification/interruption 31 (23.1%) 31 (23.1%) 32 (24.2%) + Related AE leading to withdrawal from treatment 6 (4.5%) 12 (9.0%) 8 (6.1%) + Related AE leading to dose modification/interruption 29 (21.6%) 38 (28.4%) 38 (28.8%) Severe AE (at greatest intensity) 91 (67.9%) 90 (67.2%) 93 (70.5%)